Nordic Nanovector ASA News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.12.20	Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in Diffuse Large B Cell Lymphoma (PR Newswire)
01.12.20	Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in Diffuse Large B Cell Lymphoma (PR Newswire)
30.11.20	Nordic Nanovector announces change of its Oslo Børs ticker symbol to 'NANOV' (PR Newswire)
30.11.20	Nordic Nanovector announces change of its Oslo Børs ticker symbol to 'NANOV' (PR Newswire)
19.11.20	Nordic Nanovector ASA: Results for the Third Quarter 2020 (PR Newswire)
19.11.20	Nordic Nanovector completes enrolment into second safety cohort of follicular lymphoma patients in Archer-1 Phase 1b Betalutin®/rituximab combination trial (PR Newswire)
19.11.20	Nordic Nanovector ASA: Results for the Third Quarter 2020 (PR Newswire)
19.11.20	Nordic Nanovector completes enrolment into second safety cohort of follicular lymphoma patients in Archer-1 Phase 1b Betalutin®/rituximab combination trial (PR Newswire)
16.11.20	Nordic Nanovector to Present at Upcoming Jefferies Virtual London Healthcare Conference (PR Newswire)
16.11.20	Nordic Nanovector to Present at Upcoming Jefferies Virtual London Healthcare Conference (PR Newswire)
16.11.20	Nordic Nanovector ASA: Invitation to Q3 2020 Results Presentation and Webcast (PR Newswire)
16.11.20	Nordic Nanovector ASA: Invitation to Q3 2020 Results Presentation and Webcast (PR Newswire)
21.10.20	Nordic Nanovector ASA: Cancellation of Repair Offering (PR Newswire)
21.10.20	Nordic Nanovector ASA: Cancellation of Repair Offering (PR Newswire)
21.10.20	Nordic Nanovector ASA: Extraordinary general meeting held (PR Newswire)
21.10.20	Nordic Nanovector ASA: Extraordinary general meeting held (PR Newswire)
19.10.20	Nordic Nanovector ASA - Streaming details for EGM (PR Newswire)
19.10.20	Nordic Nanovector ASA - Streaming details for EGM (PR Newswire)
08.10.20	Nordic Nanovector publishes results of preclinical study demonstrating Betalutin® reverses tumour resistance to rituximab in NHL disease models (PR Newswire)
08.10.20	Nordic Nanovector publishes results of preclinical study demonstrating Betalutin® reverses tumour resistance to rituximab in NHL disease models (PR Newswire)
30.09.20	Nordic Nanovector ASA - Notice of extraordinary general meeting (PR Newswire)
30.09.20	Nordic Nanovector ASA - Tranche 1 share capital increase registered (PR Newswire)
25.09.20	Nordic Nanovector ASA: Prospectus approved (PR Newswire)
25.09.20	Nordic Nanovector ASA - Tranche 2 share capital increase registered (PR Newswire)
24.09.20	Nordic Nanovector ASA - Key information regarding potential repair offering (PR Newswire)
24.09.20	Nordic Nanovector - Private placement successfully completed (PR Newswire)
23.09.20	Nordic Nanovector launches a private placement of new shares (PR Newswire)
03.09.20	Nordic Nanovector - Mature Data from the LYMRIT 37-01 - Part A trial, Published in Blood Advances (PR Newswire)
03.09.20	Nordic Nanovector - Mature Data from the LYMRIT 37-01 - Part A trial, Published in Blood Advances (PR Newswire)
01.09.20	Nordic Nanovector to Present at Upcoming Pareto Securities 11 th Healthcare Conference (PR Newswire)
01.09.20	Nordic Nanovector to Present at Upcoming Pareto Securities 11 th Healthcare Conference (PR Newswire)
27.08.20	Nordic Nanovector ASA: Results for the Second Quarter and First Half 2020 (PR Newswire)
27.08.20	Nordic Nanovector ASA: Results for the Second Quarter and First Half 2020 (PR Newswire)
21.08.20	Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2020 Results Presentation and Webcast - correction (PR Newswire)
21.08.20	Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2020 Results Presentation and Webcast - correction (PR Newswire)
21.08.20	Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2020 Results Presentation and Webcast (PR Newswire)
21.08.20	Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2020 Results Presentation and Webcast (PR Newswire)
10.08.20	Nordic Nanovector Appoints Dr Christine Wilkinson Blanc as Chief Medical Officer (PR Newswire)
10.08.20	Nordic Nanovector Appoints Dr Christine Wilkinson Blanc as Chief Medical Officer (PR Newswire)
06.08.20	Independent Review Committee Recommends Nordic Nanovector to focus on one dosage arm for the Pivotal PARADIGME Phase 2b Trial in Patients with 3L R/R FL (PR Newswire)
06.08.20	Independent Review Committee Recommends Nordic Nanovector to focus on one dosage arm for the Pivotal PARADIGME Phase 2b Trial in Patients with 3L R/R FL (PR Newswire)
30.07.20	Nordic Nanovector Announces EU Patent Granted Covering the Use of Alpha37 (PR Newswire)
30.07.20	Nordic Nanovector Announces EU Patent Granted Covering the Use of Alpha37 (PR Newswire)
01.07.20	Nordic Nanovector ASA - Share Capital Increase Registered (PR Newswire)
01.07.20	Nordic Nanovector ASA - Share Capital Increase Registered (PR Newswire)
01.07.20	Nordic Nanovector ASA: Allocation of Restricted Stock Unites (RSUs) to the Board of Directors (PR Newswire)
01.07.20	Nordic Nanovector ASA: Allocation of Restricted Stock Unites (RSUs) to the Board of Directors (PR Newswire)
30.06.20	Nordic Nanovector to Amend PARADIGME Trial Protocol to Expand Eligible Patient Population (PR Newswire)
30.06.20	Nordic Nanovector to Amend PARADIGME Trial Protocol to Expand Eligible Patient Population (PR Newswire)
29.06.20	Nordic Nanovector's Betalutin® Receives Fast-track Designation from US FDA for Marginal Zone Lymphoma (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Roche Hldg G	255.50	0.75 %	K V
Nestle	74.88	0.62 %	K V
CieFinRichemont	137.90	0.40 %	K V
Swiss Life Hldg	699.60	0.32 %	K V
Swisscom	504.50	0.30 %	K V
Sika	215.80	-0.37 %	K V
Givaudan	3’966.00	-0.40 %	K V
Lonza Grp	535.80	-0.41 %	K V
Geberit	514.60	-0.46 %	K V
ABB	49.07	-0.95 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Nordic Nanovector ASA

Aktien Top/Flop

Meistgelesene Nachrichten